Lazard Capital Upgrades Biogen Idec (BIIB) to Buy
More News related to BIIB
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
More News related to Upgrades
- Credit Suisse Raises Rating on European Equities from Underweight to Overweight
- Canaccord Adams Upgrades Pan American Silver (PAAS) to Buy
- National Bank Upgrades Pengrowth Energy (PGH) to Outperform
- Ardour Capital Upgrades Capstone Turbine (CPST) to Accumulate
- Global Hunter Securities Upgrades Petroleum Development Corp. (PETD) to Buy
Lazard Capital upgrades Biogen Idec (Nasdaq: BIIB) from Hold to Buy with a $56 price target.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
+0.10Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
